Considering that a 7-day rosiglitazone oral treatment results in concentrations of 260–450 nM in the human brain30, this unusual dose-response in vitro study suggests that a new therapeutic application of PPAR-γ agonist for AD should be considered at a lower dose than the conventional dose used to treat diabetes. This evidence concerns the gene PPARG and Alzheimer disease.